


# Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice

Alexandra Fauvre\*, Chiara Ursino\*, Veronique Garambois, Elodie Culierier, Lois-Antoine Milazzo, Nadia Vezzio-Vié, L Jeanson, Candice Marchive, AF Andrade, Eve Combes, Salima Atis, G Lossaint, F Quenet, Henri-Alexandre Michaud, Lakhdar Khellaf, I Corbeau, Diego Tosi, Nadine Houede, Nathalie Bonnefoy, Sgarbura Olivia, Céline Gongora#, and Julien Faget#.

\* These authors contributed equally as first author

# These authors contributed equally as principal investigator and corresponding author.



- ⇒ Combination of VE-822 + oxaliplatin (Vox) and anti-PD-1 antibody completely cured CRC-bearing mice and protected them from tumor rechallenge.
- ⇒ Vox deeply altered neutrophil biogenesis and induced the accumulation of Ly6C<sup>+</sup>PD-1<sup>+</sup>CD8<sup>+</sup> T cells in the mouse blood and spleen.
- ⇒ Vox + anti-PD-1 immunotherapy could overcome oxaliplatin resistance.